Allergan, Inc and ExonHit Therapeutics have expanded their current drug discovery collaboration until December 2011. The current agreement, focused on finding drug treatments for neurodegenerative diseases and pain as well as ophthalmic targets, was established in 2003 and, following two previous extensions due to success, was due to expire in December 2009.
Eyes treated with peripheral retinal cryotherapy lose accommodative amplitude after surgery, according to results of a study published in the January 2009 issue of the American Journal of Ophthalmology.
Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.
The Scottish Braille Printing Press, the leading provider of Braille books in the UK, has launched an appeal to raise GBP 2 million (approximately E2.1 million).
NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product.
Latisse (bimatoprost solution 0.03%) (Allergan, Inc) has been recommended for FDA approval as a treatment for hypertrichosis of the eyelashes.
Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
Influence of Conjunctival Suture Removal on the Outcome of Trabeculectomy
Evaluation of anterior segment parameter changes using the Pentacam after uneventful phacoemulsification
The Gold Standard: Argon Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty
Prevention of cadmium accumulation in retinal pigment epithelium with manganese and zinc
Clinical Detection of Precataractous Lens Protein Changes Using Dynamic Light Scattering
Effect of TNF-alpha on human ARPE-19-secreted proteins
Pain Relief for Strabismus Surgery in Children- a Randomised Controlled Study of the use of Preoperative Subtenon's Levobupivacaine
A pilot study using Iluvien (an intravitreal insert delivering fluocinolone acetonide) to treat geographic atrophy secondary to age-related macular degeneration (AMD) has begun enrolling patients, according to a statement from Alimera Sciences Inc, the developer of Iluvien.
Ethambutol induces PKC-dependent cytotoxic and antiproliferative effects on human retinal pigment cells
Patients with type 1 diabetes who have been treated with intensive therapy have significantly lower incidences of retinopathy progression up to ten years, according to study results published in the December issue of the Archives of Ophthalmology.
Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.
New imaging techniques are allowing more objective quantification of glaucoma diagnosis and progression, according to study results published online ahead of print by the British Journal of Ophthalmology.
Current research opportunities
Current job opportunities
Please click here to read the full story.
Rolf Schwind, CEO of Schwind Eye Tech Solutions, has been presented with the Gusi Peace Prize 2008 in a ceremony held on November 24th in Manila, the Philippines.
Religiously-motivated fasting may affect glaucoma medication compliance rates, according to study results presented at the annual meeting of the American Academy of Ophthalmology (AAO).
Please click here to read the full story.
Please click here to read the full story.
Topical Endoscopic Fundal Imaging (TEFI) offers a rapid, comprehensive and non-invasive method of monitoring retinal disease progression, according to a study published in the December issue of Investigative Ophthalmology and Visual Science.
Please click here to read the full story.
Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.